Karyopharm Therapeutics, Inc. (KPTI)
6.95
-0.05
(-0.71%)
USD |
NASDAQ |
Dec 12, 16:00
6.89
-0.06
(-0.86%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Annual): 142.89M for Dec. 31, 2024
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| TG Therapeutics, Inc. | 94.29M |
| Actinium Pharmaceuticals, Inc. | 29.88M |
| Axsome Therapeutics, Inc. | 186.54M |
| Krystal Biotech, Inc. | 53.57M |
| Akebia Therapeutics, Inc. | 31.99M |